Alnylam Pharmaceuticals | ALNY - 負債





負債 変化する 日付
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
Arrowhead Research USD 366.28M 13.25M 2025-09
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
BioMarin Pharmaceutical USD 605.86M 1.62M 2025-12
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Moderna USD 1.31B 571M 2025-12
Neurocrine Biosciences USD 415.3M 13.1M 2025-12
Novartis USD 32.02B 615M 2025-09
PTC Therapeutics USD 2.71B 2.42B 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 21.76B 530M 2025-09
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Takeda JPY 4.85T 208B 2025-12
Tectonic Therapeutic USD 876K 115K 2024-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 2.03B 195.7M 2025-12
Xencor USD 69.27M 1.34M 2025-09